Latest News

Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.

The first controlled study of GLP-1 receptor agonists and nail health found nail detachment in 39% of users versus 9% of controls at EADV 2026.

Earlier bimekizumab treatment was tied to higher IHS4-100 rates at 3 years in hidradenitis suppurativa, per post hoc BE HEARD data at EADV 2026.

EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.

FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.

Heavy drinking rose >36% since 2018 among middle-aged adults. A hepatologist on screening, sex-specific thresholds, and pandemic effects.

Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.

Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.

Tulisokibart met its HiSCR50 primary endpoint at 16 weeks in the phase 2b MK-7240-012 trial assessing moderate to severe hidradenitis suppurativa.

Intralesional BO-112 met its main endpoint in the phase 2b SPOTLIGHT-204 trial, with 61% of patients with resectable basal cell carcinoma responding.

Zasocitinib achieved PASI 100 in 36.5% of patients vs 13.9% with deucravacitinib at week 16 in the phase 3 LATITUDE Atlas psoriasis trial.

The international SkinObservatory study found climate-related skin disease disproportionately affecting low-income nations at EADV 2026.

All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.

Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.

Newly published results from the TRIUMPH-1 study have indicated the direct correlation between the triple agonist and several improvements to weight.

Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.

Smoking was associated with greater odds of EPI, and prevalence ranged from 21.1% to 52.1% depending on the diagnostic test used.

Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.

Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.

Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.

Ochsner Transplant Institute director discusses liver transplant care, robotic kidney transplant, organ preservation, and access gaps.

Mirum's antibody led to virologic response and ALT normalization in up to 56% of patients at week 24, vs 0% with delayed treatment.

Murad Alam, MD, and Elizabeth Kiracofe, MD, discuss how reimbursement, coverage, and advocacy shape dermatology access for patients with skin of color.